• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗微生物药物耐药性——我们尚未意识到却近在咫尺的“真正”大流行。

Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.

作者信息

Yoo Jin-Hong

机构信息

Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

J Korean Med Sci. 2025 May 19;40(19):e161. doi: 10.3346/jkms.2025.40.e161.

DOI:10.3346/jkms.2025.40.e161
PMID:40390585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12089690/
Abstract

Antimicrobial resistance (AMR) represents a persistent and escalating public health crisis, often overlooked despite its severe global impact. Unlike acute infectious diseases, AMR progresses silently but relentlessly, posing long-term threats to health systems worldwide. This review examines the historical evolution and current epidemiology of multidrug-resistant organisms (MDROs), emphasizing the global and Korean burden of MDROs. While the development of new antibiotics remains limited, alternative therapies such as bacteriophage treatment have re-emerged as potential solutions. However, challenges in access to novel agents persist, particularly in Korea, due to regulatory, economic, and market-related barriers. To counter AMR, comprehensive strategies are essential. These include infection control, antibiotic stewardship programs (ASPs), and the development and proper allocation of new drugs. The One Health approach must integrate human, animal, and environmental health perspectives. Notably, infectious disease specialists play a central role in this fight: leading ASPs, shaping policy, engaging in public education, supporting research, and coordinating multidisciplinary collaboration. The AMR pandemic is unlikely to subside without systemic reform, sustained investment, and international cooperation. Urgent efforts must be made to address this hidden but growing threat. Recognizing AMR as a true pandemic is the first step toward containing its spread and securing the efficacy of antibiotics for future generations.

摘要

抗菌药物耐药性(AMR)是一场持续且不断升级的公共卫生危机,尽管其具有严重的全球影响,但常常被忽视。与急性传染病不同,AMR悄然却无情地发展,对全球卫生系统构成长期威胁。本综述考察了多重耐药菌(MDROs)的历史演变和当前流行病学情况,强调了MDROs在全球及韩国的负担。虽然新型抗生素的研发仍然有限,但诸如噬菌体治疗等替代疗法已重新成为潜在的解决方案。然而,由于监管、经济和市场相关障碍,获取新型药物面临的挑战依然存在,在韩国尤其如此。为应对AMR,全面的策略至关重要。这些策略包括感染控制、抗生素管理计划(ASPs)以及新药的研发和合理分配。“同一健康”方法必须整合人类、动物和环境卫生等方面的观点。值得注意的是,传染病专家在这场斗争中发挥着核心作用:领导抗生素管理计划、制定政策、开展公众教育、支持研究以及协调多学科合作。如果没有系统性改革、持续投资和国际合作,AMR大流行不太可能消退。必须立即做出努力,以应对这一隐藏但不断增长的威胁。将AMR视为真正的大流行是遏制其传播并确保抗生素对子孙后代有效的第一步。

相似文献

1
Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.抗微生物药物耐药性——我们尚未意识到却近在咫尺的“真正”大流行。
J Korean Med Sci. 2025 May 19;40(19):e161. doi: 10.3346/jkms.2025.40.e161.
2
Global antimicrobial resistance and antibiotic use in COVID-19 patients within health facilities: A systematic review and meta-analysis of aggregated participant data.全球医疗机构中 COVID-19 患者的抗菌药物耐药性和抗生素使用情况:汇总参与者数据的系统评价和荟萃分析。
J Infect. 2024 Jul;89(1):106183. doi: 10.1016/j.jinf.2024.106183. Epub 2024 May 14.
3
An Overview of the Recent Advances in Antimicrobial Resistance.抗菌药物耐药性的最新进展概述
Microorganisms. 2024 Sep 21;12(9):1920. doi: 10.3390/microorganisms12091920.
4
Exploring the intricacies of antimicrobial resistance: Understanding mechanisms, overcoming challenges, and pioneering innovative solutions.探索抗菌素耐药性的复杂性:理解其机制、克服挑战并开创创新解决方案。
Eur J Pharmacol. 2025 Jul 5;998:177511. doi: 10.1016/j.ejphar.2025.177511. Epub 2025 Mar 14.
5
Bacterial Epidemiology and Antimicrobial Resistance Profiles in Children Reported by the ISPED Program in China, 2016 to 2020.中国 ISPED 项目报告的 2016 至 2020 年儿童细菌流行病学和抗菌药物耐药性特征。
Microbiol Spectr. 2021 Dec 22;9(3):e0028321. doi: 10.1128/Spectrum.00283-21. Epub 2021 Nov 3.
6
Defeating the Silent Enemy: Antimicrobial Resistance Looming as the Next Global Pandemic.战胜无声的敌人:下一个全球大流行的隐忧——抗菌药物耐药性。
J Assoc Physicians India. 2024 Mar;72(3):66-72. doi: 10.59556/japi.72.0487.
7
Impact of a Comprehensive Antimicrobial Stewardship Program on Institutional Burden of Antimicrobial Resistance: A 14-Year Controlled Interrupted Time-series Study.综合抗菌药物管理计划对抗菌药物耐药性的机构负担的影响:一项 14 年的对照中断时间序列研究。
Clin Infect Dis. 2020 Dec 31;71(11):2897-2904. doi: 10.1093/cid/ciz1183.
8
A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future.一篇关于日本管理抗生素耐药性感染危机的药物开发的叙事性综述:过去、现在和未来。
Expert Rev Anti Infect Ther. 2022 Dec;20(12):1603-1614. doi: 10.1080/14787210.2022.2142118. Epub 2022 Nov 15.
9
Principles and practices of antimicrobial stewardship programs in Korea.韩国抗菌药物管理计划的原则与实践。
Korean J Intern Med. 2024 May;39(3):373-382. doi: 10.3904/kjim.2023.482. Epub 2024 Apr 23.
10
Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight?COVID-19 时代的抗菌多药耐药性:被遗忘的困境?
Antimicrob Resist Infect Control. 2021 Jan 29;10(1):21. doi: 10.1186/s13756-021-00893-z.

本文引用的文献

1
Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.用于多重耐药感染的噬菌体疗法:当前技术与治疗方法
J Clin Invest. 2025 Mar 3;135(5):e187996. doi: 10.1172/JCI187996.
2
Prevalence and mortality associated with multidrug-resistant infections in adult intensive care units in Argentina (PREV-AR).阿根廷成人重症监护病房多重耐药感染的患病率及死亡率(PREV-AR)。
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0142624. doi: 10.1128/aac.01426-24. Epub 2025 Jan 22.
3
Quantitative and qualitative evaluation of antimicrobial usage: the first step for antimicrobial stewardship.抗菌药物使用的定量和定性评估:抗菌药物管理的第一步。
Korean J Intern Med. 2024 May;39(3):383-398. doi: 10.3904/kjim.2023.506. Epub 2024 Apr 30.
4
A Brief History of Antimicrobial Resistance.抗菌药物耐药性简史。
AMA J Ethics. 2024 May 1;26(5):E408-417. doi: 10.1001/amajethics.2024.408.
5
The Global and Regional Prevalence of Hospital-Acquired Carbapenem-Resistant Infection: A Systematic Review and Meta-analysis.医院获得性耐碳青霉烯类感染的全球及区域患病率:一项系统评价与荟萃分析
Open Forum Infect Dis. 2023 Dec 19;11(2):ofad649. doi: 10.1093/ofid/ofad649. eCollection 2024 Feb.
6
Carbapenem-Resistant Gram-Negative Bacilli Characterization in a Tertiary Care Center from El Bajio, Mexico.墨西哥巴伊奥地区一家三级医疗中心耐碳青霉烯革兰氏阴性杆菌的特征分析
Antibiotics (Basel). 2023 Aug 8;12(8):1295. doi: 10.3390/antibiotics12081295.
7
Antimicrobial Resistance: A Growing Serious Threat for Global Public Health.抗菌药物耐药性:对全球公共卫生日益严重的威胁。
Healthcare (Basel). 2023 Jul 5;11(13):1946. doi: 10.3390/healthcare11131946.
8
A 7-Year Brazilian National Perspective on Plasmid-Mediated Carbapenem Resistance in Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex and the Impact of the Coronavirus Disease 2019 Pandemic on Their Occurrence.巴西国家层面上肠杆菌科、铜绿假单胞菌和鲍曼不动杆菌中质粒介导碳青霉烯类耐药性的 7 年观察结果以及 2019 年冠状病毒病大流行对其发生的影响。
Clin Infect Dis. 2023 Jul 5;77(Suppl 1):S29-S37. doi: 10.1093/cid/ciad260.
9
Changing Epidemiology of Pathogenic Bacteria Over the Past 20 Years in Korea.过去 20 年韩国病原菌的流行病学变化
J Korean Med Sci. 2023 Mar 13;38(10):e73. doi: 10.3346/jkms.2023.38.e73.
10
Emergence of NDM-1-producing Sequence Type 773 Clone: Shift of Carbapenemase Molecular Epidemiology and Spread of 16S rRNA Methylase Genes in Korea.产 NDM-1 的序列型 773 克隆的出现:韩国碳青霉烯酶分子流行病学的转变和 16S rRNA 甲基化酶基因的传播。
Ann Lab Med. 2023 Mar 1;43(2):196-199. doi: 10.3343/alm.2023.43.2.196. Epub 2022 Oct 25.